



Australian Government

Department of Health
Therapeutic Goods Administration

Ms Amy Caplette
Executive Director of Quality Assurance
Thorne Research Inc.
620 Omni Industrial Boulevard
Summerville South Carolina 29486
United States of America

Our Reference: E18-279550

Dear Ms Caplette,

Subject: Issue of GMP certificate MI-2018-CE-03126-1

Please find enclosed the GMP certificate for your manufacturing premises.

The certificate remains valid only if re-inspections are conducted when scheduled by the Therapeutic Goods Administration. The inspection frequency is not a reflection of the expiry date shown on the certificate but is consistent with the re-inspection frequency applicable to Australian manufacturers of the same class of products.

The Therapeutic Goods Administration will contact the relevant sponsor/s to arrange the re-inspection of your facility.

Yours sincerely,

Signed and authorised by

Robert Prestridge
Senior Inspector
Manufacturing Quality Branch

8 February 2019

Contact: gmp@tga.gov.au, phone +61 2 6221 6881 or fax +61 2 6232 8426



Australian Government

Department of Health
Therapeutic Goods Administration

Certificate of GMP Compliance of a Manufacturer

Certificate Number:

MI-2018-CE-03126-1

Issued to:

Thorne Research Inc.

Manufacturing Site Address:

620 Omni Industrial Boulevard
Summerville South Carolina 29486
United States of America

The Therapeutic Goods Administration, the Competent Authority of Australia, confirms that this manufacturer has been inspected following section/s 25(1)(g), 26(1)(g) and/or 26A(3) of the *Therapeutic Goods Act 1989* in connection with marketing authorisation/s listing manufacturers located outside Australia.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 25 to 26 October 2018, it is considered that the manufacturer complies with the Good Manufacturing Practice requirements of the PIC/S Guide to Good Manufacturing Practice for Medicinal Products – 1 January 2017.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above. This certificate remains valid until the expiry date provided that re-inspections are conducted as determined by the Therapeutic Goods Administration as the issuing Authority. This certificate should not be relied upon to reflect the compliance status after the expiry date.

EXPIRY DATE: 26 October 2021

ISSUE DATE: 8 February 2018

This Certificate remains valid only if re-inspections are conducted when scheduled by the Therapeutic Goods Administration.
The authenticity of this Certificate may be verified with the Therapeutic Goods Administration as the issuing authority.

PO Box 100 Woden ACT 2606 ABN 40 939 406 804
Phone: 02 6232 8644 Fax: 02 6203 1605 Email: info@tga.gov.au www.tga.gov.au

TGA Health Safety
Regulation



Australian Government

Department of Health
Therapeutic Goods Administration

Certificate of GMP Compliance of a Manufacturer

Certificate Number:

MI-2018-CE-03126-1

MANUFACTURING OPERATIONS

This certificate covers the following steps in the manufacture of therapeutic goods at the manufacturing site address specified above.

Manufacturing Type	Sterility	Dosage Form	Product Category	Manufacturing Step
Medicine manufacture	Non Sterile	Capsule; hard	Listed Therapeutic Good	Finished Product Manufacture
Medicine manufacture	Non Sterile	Powder	Listed Therapeutic Good	Finished Product Manufacture

This Certificate remains valid only if re-inspections are conducted when scheduled by the Therapeutic Goods Administration. The authenticity of this Certificate may be verified with the Therapeutic Goods Administration as the issuing authority.